Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study
Abstract
Question: Is metformin use associated with diminished risk of cardiometabolic diseases and related mortality in cancer survivors? If so, what mechanisms contribute to this inverse association with cardiometabolic risk? Findings: In this cohort study of 3995 cancer survivors over a median period of 6.42 years, metformin use was correlated with decreased risks of cardiometabolic diseases, all-cause and cardiometabolic mortality, likely due to its oxidative stress antagonism. Meaning: These study findings indicated that metformin use was associated with improved cardiometabolic health, leading to enhanced overall survival and quality of life in cancer survivors. Moreover, targeting oxidative stress may be crucial in developing cardiometabolic protective drugs for patients with cancer in the future. Background In the USA, the prolonged effective survival of cancer population has brought significant attention to the rising risk of cardiometabolic morbidity and mortality in this population. This heightened risk underscores the urgent need for research into effective pharmacological interventions for cancer survivors. Notably, metformin, a well-known metabolic regulator with pleiotropic effects, has shown protective effects against cardiometabolic disorders in diabetic individuals. Despite these promising indications, evidence supporting its efficacy in improving cardiometabolic outcomes in cancer survivors remains scarce. Methods A prospective cohort was established using a…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.